Literature DB >> 15137959

Chemotherapy and radiation of anal canal cancer: the first approach.

Cathy Eng1, James Abbruzzese, Bruce D Minsky.   

Abstract

Since the late 1970's, increasing evidence from single-arm phase II studies has indicated that combined modality therapy yields a complete response rate of approximately 80-90% in most patients with squamous cell cancers of the anal canal. Surgery, most commonly an abdominoperineal resection, is reserved for salvage therapy. Although patients with large primary tumors (>5 cm) have a lower complete response rate of 50-75%, the majority of patients may be spared a colostomy and have an excellent overall survival. This chapter reviews the recent literature of patients treated for squamous cell, basaloid, and cloacogenic carcinoma (collectively defined as squamous cell cancer) of the anal canal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15137959     DOI: 10.1016/j.soc.2003.12.004

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  3 in total

Review 1.  The current landscape of locally advanced rectal cancer.

Authors:  Mebea Aklilu; Cathy Eng
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

2.  Breast cancer local recurrence under the form of inflammatory carcinoma, treated with concurrent radiation and chemotherapy, a case report.

Authors:  Isabel Reis; Helena Pereira; Isabel Azevedo; João Conde; Isabel Bravo; Rogéria Craveiro; Deolinda Pereira
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-20

3.  The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.

Authors:  Cathy Eng; George J Chang; Y Nancy You; Prajnan Das; Miguel Rodriguez-Bigas; Yan Xing; Jean-Nicolas Vauthey; Jane E Rogers; Aki Ohinata; Priyanka Pathak; Salil Sethi; Jonathan K Phillips; Christopher H Crane; Robert A Wolff
Journal:  Oncotarget       Date:  2014-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.